Orphan and rare diseases drug company Lobe Sciences Ltd. LOBEF is set to acquire Altemia & Company LLC.
The deal includes all Altemnia assets, intellectual property, and commercial inventory to manage patients suffering from Sickle Cell Disease (SCD), a group of hereditary red blood cell (RBC) disorders causing pain and vaso-occlusive events.
SCD may result in anemia, infection, acute chest syndrome and stroke, all of which causes populations with SCD to have a shortened life span.
Patent-pending Altemia is a proprietary oral emulsion mix that aims to reduce inflammation associated in adults with SCD, and enters within the “medical food” category. The company has no current or long-term liabilities.
Deal Terms: Altemia shareholders would receive a total $2.8 (CA$2.8) million in the form of a pro-rata basis aggregated 76 million Lobe common shares at $0.037 each. Lobe would pay a tiered royalty of up to 10% on annual net sales of $92 million and issue 3 million warrants upon the first $14 million in sales.
What’s Next: Lobe CEO Philip Young said the company plans to sell the clinically validated product globally, starting in the second half of this year.
The soon-to-be-acquired product will add commercial revenue “this year and beyond,” by targeting the 55 major SCD clinics in the U.S. Lobe would use revenues to fund ongoing and planned clinical activities with its psychedelic-inspired L-130 and L-131, Young says.
Altemia will be “positioned as a cost-effective medical food option for patients and payers seeking alternatives to drug products with significant side effects,” he said.
Lobe also acquired clinical-stage SAN100, a prescription drug alternative for the treatment of SCD uniquely in children.
SCD affects some 100,000 people in the U.S. alone, occurring among one in every 500 Black or African American births and 1 out of every 36,000 Hispanic American births, while there are millions of patients in the Middle East, Africa and India.
Healing CREI Forms Strategic Alliance with Heally
Real estate investment company Healing CREI is partnering with SaaS platform Heally Inc. ,
Both companies have a shared vision on how to address the mental health crisis, which is the foundation for the strategic alliance, according to Healing CREI president and psychedelics investor Cody Shandraw.
”By combining our strengths, we can provide complementary and alternative medicine clinics and clinicians with access to premium real estate locations and cutting-edge telemedicine technology, ultimately improving patient care,” Shandraw said.
Heally’s network connects patients with holistic medicine providers for in-person or online consultations, functioning as a complementary healthcare system. The partnership is set to help Heally expand its distribution network and drive brand awareness for its SaaS platform and other product offerings.
More On Healing CREI: Check Out This Canadian Company Building On Several Vertical Psychedelics Businesses
Photo: Benzinga edit with photo by Pexels.